Regulation of insulin signaling by the phosphatidylinositol 3,4,5-triphosphate phosphatase SKIP through the scaffolding function of Pak1

Molecular and Cellular Biology

Volumn 32, Issue 17, 2012, Pages 3570-3584

  Ijuin, Takeshi ^a   Takenawa, Tadaomi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; MULTIPROTEIN COMPLEX; P21 ACTIVATED KINASE 1; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B BETA; RAC1 PROTEIN; SCAFFOLD PROTEIN; SKELETAL MUSCLE AND KIDNEY ENRICHED INOSITOL POLYPHOSPHATE PHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; GLUCOSE TRANSPORT; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RAT;

ANIMALS; CELL LINE; GLUCOSE; HUMANS; INSULIN; MICE; P21-ACTIVATED KINASES; PHOSPHATIDYLINOSITOL PHOSPHATES; PHOSPHORIC MONOESTER HYDROLASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RAC1 GTP-BINDING PROTEIN; RATS; SIGNAL TRANSDUCTION;

EID: 84866289860     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00636-12     Document Type: Article

References (36)

1. Bishop AL, Hall A. 2000. Rho GTPases and their effector proteins. Biochem. J. 348(Part 2):241-255.
2. Carpten JD, et al. 2007. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448:439-444.
3. Cho H, et al. 2001. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292: 1728-1731.
4. Christoforidis S, Zerial M. 2000. Purification and identification of novel Rab effectors using affinity chromatography. Methods 20:403-410.
5. Dugani CB, Klip A. 2005. Glucose transporter 4: cycling, compartments and controversies. EMBO Rep. 6:1137-1142.
6. Gao X, Zhang J. 2008. Spatiotemporal analysis of differential Akt regulation in plasma membrane microdomains. Mol. Biol. Cell 19:4366-4373.
7. Garofalo RS, et al. 2003. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J. Clin. Invest. 112:197-208.
8. George S, et al. 2004. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 304:1325-1328.
9. Gurung R, et al. 2003. Identification of a novel domain in two mammalian inositol-polyphosphate 5-phosphatases that mediates membrane ruffle localization. The inositol 5-phosphatase skip localizes to the endoplasmic reticulum and translocates to membrane ruffles following epidermal growth factor stimulation. J. Biol. Chem. 278:11376-11385.
10. Higuchi M, Onishi K, Kikuchi C, Gotoh Y. 2008. Scaffolding function of PAK in the PDK1-Akt pathway. Nat. Cell Biol. 10:1356-1364.
11. Hussain K, et al. 2011. An activating mutation of AKT2 and human hypoglycemia. Science 334:474.
12. Ijuin T, et al. 2000. Identification and characterization of a novel inositol polyphosphate 5-phosphatase. J. Biol. Chem. 275:10870-10875.
13. Ijuin T, Takenawa T. 2012. Regulation of insulin signaling and glucose transporter 4 (GLUT4) exocytosis by phosphatidylinositol 3,4,5-trisphosphate (PIP3) phosphatase, skeletal muscle, and kidney enriched inositol polyphosphate phosphatase (SKIP). J. Biol. Chem. 287:6991-6999.
14. Ijuin T, Takenawa T. 2003. SKIP negatively regulates insulin-induced GLUT4 translocation and membrane ruffle formation. Mol. Cell. Biol. 23:1209-1220.
15. Ijuin T, et al. 2008. Increased insulin action in SKIP heterozygous knockout mice. Mol. Cell. Biol. 28:5184-5195.
16. Ishii K, et al. 1994. Epidermal growth factor triggers the translocation of insulin-responsive glucose transporter (GLUT4). Biochem. Biophys. Res. Commun. 205:857-863.
17. Jacobs C, Onnockx S, Vandenbroere I, Pirson I. 2004. Endogenous SHIP2 does not localize in lipid rafts in 3T3-L1 adipocytes. FEBS Lett. 565:70-74.
18. Kamohara S, et al. 1995. Platelet-derived growth factor triggers translocation of the insulin-regulatable glucose transporter (type 4) predominantly through phosphatidylinositol 3-kinase binding sites on the receptor. Proc. Natl. Acad. Sci. U. S. A. 92:1077-1081.
19. Komander D, et al. 2004. Structural insights into the regulation of PDK1 by phosphoinositides and inositol phosphates. EMBO J. 23:3918-3928.
20. Lei M, et al. 2000. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell 102:387-397.
21. Parrini MC, Lei M, Harrison SC, Mayer BJ. 2002. Pak1 kinase homodimers are autoinhibited in trans and dissociated upon activation by Cdc42 and Rac1. Mol. Cell 9:73-83.
22. Pieper GM, Meier DA, Hager SR. 1995. Endothelial dysfunction in a model of hyperglycemia and hyperinsulinemia. Am. J. Physiol. 269:H845-H850.
23. Pilling C, Landgraf KE, Falke JJ. 2011. The GRP1 PH domain, like the AKT1 PH domain, possesses a sentry glutamate residue essential for specific targeting to plasma membrane PI(3,4,5)P(3). Biochemistry 50:9845-9856.
24. Saltiel AR. 2001. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104:517-529.
25. Sarbassov DD, et al. 2004. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14:1296-1302.
26. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307:1098-1101.
27. Sleeman MW, et al. 2005. Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nat. Med. 11:199-205.
28. Sowers JR, et al. 1993. Hyperinsulinemia, insulin resistance, and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am. J. Hypertens. 6:260S-270S.
29. Török D, et al. 2004. Insulin but not PDGF relies on actin remodeling and on VAMP2 for GLUT4 translocation in myoblasts. J. Cell Sci. 117:5447-5455.
30. Tsakiridis T, Taha C, Grinstein S, Klip A. 1996. Insulin activates a p21-activated kinase in muscle cells via phosphatidylinositol 3-kinase. J. Biol. Chem. 271:19664-19667.
31. Ueda S, et al. 2010. Crucial role of the small GTPase Rac1 in insulinstimulated translocation of glucose transporter 4 to the mouse skeletal muscle sarcolemma. FASEB J. 24:2254-2261.
32. Whiteman EL, Chen JJ, Birnbaum MJ. 2003. Platelet-derived growth factor (PDGF) stimulates glucose transport in 3T3-L1 adipocytes overexpressing PDGF receptor by a pathway independent of insulin receptor substrates. Endocrinology 144:3811-3820.
33. Wijesekara N, et al. 2005. Muscle-specific Pten deletion protects against insulin resistance and diabetes. Mol. Cell. Biol. 25:1135-1145.
34. Yuasa T, et al. 2004. Platelet-derived growth factor stimulates glucose transport in skeletal muscles of transgenic mice specifically expressing platelet-derived growth factor receptor in the muscle, but it does not affect blood glucose levels. Diabetes 53:2776-2786.
35. Zenke FT, King CC, Bohl BP, Bokoch GM. 1999. Identification of a central phosphorylation site in p21-activated kinase regulating autoinhibition and kinase activity. J. Biol. Chem. 274:32565-32573.
36. Zhou QL, et al. 2004. Analysis of insulin signalling by RNAi-based gene silencing. Biochem. Soc. Trans. 32:817-821.